日期:
2020 年 — 2026 年
2020
2021
2022
2023
2024
2025
2026
影响因子:

Adjuvant Pembrolizumab Versus Placebo for Renal Cell Carcinoma in the East Asian Subgroup of the Phase 3 KEYNOTE-564 Study

KEYNOTE-564 III期研究东亚亚组中肾细胞癌辅助治疗帕博利珠单抗与安慰剂的比较

Park, Se Hoon; Chang, Yen-Hwa; Lee, Jae Lyun; Choueiri, Toni K; Kimura, Go; Chung, Jinsoo; Masumori, Naoya; Nishimura, Kazuo; Kato, Minoru; Kato, Haruaki; Numakura, Kazuyuki; Chang, Chao-Hsiang; Anai, Satoshi; Tsunemori, Hiroyuki; Chen, Chung-Hsin; Lin, Jianxin; Elfiky, Aymen; Burgents, Joseph E; Kitamura, Hiroshi

A Minimum 3-Year Follow-Up of Nivolumab-Plus-Ipilimumab in Japanese Patients With Advanced or Metastatic Renal Cell Carcinoma: A Final Analysis of the J-ENCORE Study

一项针对日本晚期或转移性肾细胞癌患者的纳武利尤单抗联合伊匹木单抗治疗的至少3年随访研究:J-ENCORE研究的最终分析

Hamamoto, Shuzo; Nozawa, Masahiro; Shirotake, Suguru; Sazuka, Tomokazu; Numakura, Kazuyuki; Mizokami, Atsushi; Kondo, Tsunenori; Naito, Sei; Abe, Takashige; Ohba, Kojiro; Kimura, Go; Nagata, Masayoshi; Onodera, Shunta; Yamaguchi, Katsumi; Uemura, Hirotsugu

Outcomes of Nivolumab-Plus-Ipilimumab in Metastatic Renal Cell Carcinoma: Second Interim Analysis of the J-ENCORE Study

纳武利尤单抗联合伊匹木单抗治疗转移性肾细胞癌的疗效:J-ENCORE 研究的第二次中期分析

Sazuka, Tomokazu; Tatsugami, Katsunori; Shirotake, Suguru; Hamamoto, Shuzo; Nozawa, Masahiro; Numakura, Kazuyuki; Mizokami, Atsushi; Kondo, Tsunenori; Naito, Sei; Abe, Takashige; Ohba, Kojiro; Kimura, Go; Onodera, Shunta; Yamaguchi, Katsumi; Uemura, Hirotsugu

Neoadjuvant Chemohormonal Therapy for Patients With Very-high Risk Localized Prostate Cancer in Clinical Stages T2 and T3a

对临床分期为T2和T3a期的极高危局限性前列腺癌患者进行新辅助化疗及激素治疗

Kikuchi, Daiki; Numakura, Kazuyuki; Miyauchi, Kotona; Abe, Noriyuki; Ohtani, Miyu; Kobayashi, Shin; Wada, Naoki

Comparison of IO-IO and IO-TKI Treatment Outcomes in Metastatic Renal Cell Carcinoma: Influence of Metastatic Site Count

转移性肾细胞癌中 IO-IO 和 IO-TKI 治疗结果的比较:转移部位数量的影响

Kikuchi, Hiroshi; Osawa, Takahiro; Naito, Sei; Numakura, Kazuyuki; Tokairin, Ojiro; Takai, Yuki; Sekine, Yuya; Miyata, Haruka; Matsumoto, Ryuji; Abe, Takashige; Ito, Yoichi; Habuchi, Tomonori; Tsuchiya, Norihiko; Shinohara, Nobuo

Comparative transcriptome atlas as an assistive modality for complex classification of rare kidney cancers

比较转录组图谱作为罕见肾癌复杂分类的辅助手段

Jikuya, Ryosuke; Johnson, Todd A; Muraoka, Erika; Noguchi, Go; Maekawa, Shigekatsu; Obara, Wataru; Numakura, Kazuyuki; Habuchi, Tomonori; Maejima, Kazuhiro; Sasagawa, Shota; Kanazashi, Yuki; Lee, Hwajin; Song, Woo Jeung; Sasagawa, Hajime; Mitome, Taku; Ohtake, Shinji; Kawaura, Sachi; Iribe, Yasuhiro; Aomori, Kota; Nagasaka, Hirotaka; Tatenuma, Tomoyuki; Ueno, Daiki; Komeya, Mitsuru; Ito, Hiroki; Ito, Yusuke; Muraoka, Kentaro; Kawahara, Takashi; Furuya, Mitsuko; Kato, Ikuma; Hamanoue, Haruka; Nishiyama, Akira; Tamura, Tomohiko; Baba, Masaya; Suda, Toshio; Kodama, Tatsuhiko; Ogawa, Takehiko; Uemura, Hiroji; Yao, Masahiro; Tsuzuki, Toyonori; Nagashima, Yoji; Miura, Yuji; Kimura, Go; Imoto, Seiya; Momozawa, Yukihide; Fujii, Satoshi; Makiyama, Kazuhide; Hasegawa, Takanori; Shuch, Brian M; Ricketts, Christopher J; Schmidt, Laura S; Linehan, W Marston; Nakagawa, Hidewaki; Hasumi, Hisashi

IGFBP2 alteration contributes to prostate cancer progression by modulating prostate stroma activation

IGFBP2 的改变通过调节前列腺间质活化促进前列腺癌的进展。

Huang, Mingguo; Narita, Shintaro; Sato, Hiromi; Sekine, Yuya; Kobayashi, Mizuki; Kashima, Soki; Yamamoto, Ryohei; Koizumi, Atsushi; Nara, Taketoshi; Numakura, Kazuyuki; Saito, Mitsuru; Nanjo, Hiroshi; Ikezoe, Takayuki; Habuchi, Tomonori

Inhibition of Fatty Acid-Binding Protein 4 Limits High-Fat-Diet-Associated Prostate Tumorigenesis and Progression in TRAMP Mice

抑制脂肪酸结合蛋白4可限制TRAMP小鼠高脂饮食相关的前列腺肿瘤发生和进展

Huang, Mingguo; Narita, Shintaro; Sato, Hiromi; Sekine, Yuya; Kobayashi, Mizuki; Kashima, Soki; Yamamoto, Ryohei; Koizumi, Atsushi; Nara, Taketoshi; Numakura, Kazuyuki; Saito, Mitsuru; Nanjo, Hiroshi; Ikezoe, Takayuki; Habuchi, Tomonori

Primary resistance to nivolumab plus ipilimumab therapy affects second-line treatment outcomes in patients with metastatic renal cell carcinoma

对纳武利尤单抗联合伊匹木单抗治疗的原发性耐药会影响转移性肾细胞癌患者的二线治疗结果。

Mori, Kanami; Numakura, Kazuyuki; Matsushita, Yuto; Kojima, Takahiro; Osawa, Takahiro; Sazuka, Tomokazu; Hatakeyama, Shingo; Goto, Keisuke; Yamana, Kazutoshi; Kandori, Shuya; Kimura, Takahiro; Nishiyama, Naotaka; Bando, Yukari; Fujita, Kazutoshi; Ueda, Kosuke; Tanaka, Hajime; Tomida, Ryotaro; Kurahashi, Toshifumi; Kitamura, Hiroshi; Miyake, Hideaki; Habuchi, Tomonori

Efficacy of modified enfortumab vedotin ineligible criteria (mEVITA) in advanced urothelial carcinoma

改良版恩福妥单抗不符合入组标准(mEVITA)在晚期尿路上皮癌中的疗效

Fukushima, Takafumi; Numakura, Kazuyuki; Shinohara, Masanao; Kawashima, Yohei; Sekine, Yuya; Mori, Kanami; Kobayashi, Mizuki; Asanuma, Himawari; Ichiyama, Takaki; Sakurai, Hisashi; Ozaki, Kai; Fujita, Naoki; Okamoto, Teppei; Yamamoto, Hayato; Yoneyama, Takahiro; Sato, Satoshi; Habuchi, Tomonori; Ohyama, Chikara; Hatakeyama, Shingo